What is LOPJLB’s current signal on ALGS?

LOPJLB’s latest quantitative signal on Aligos Therapeutics, Inc. (ALGS) is SELL in a RECOVERY regime. Signals are updated daily.

What market regime is ALGS in?

Aligos Therapeutics, Inc. (ALGS) is currently classified in the RECOVERY HMM market regime on LOPJLB.

What does Aligos Therapeutics, Inc. (ALGS) do?

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset…

Aligos Therapeutics, Inc. (ALGS)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$5.34+0.56%Close

SELLRECOVERY · day 10

Company news

gurufocus.com · 12h ago

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

globenewswire.com · 7d ago

Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

gurufocus.com · 15d ago

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

defenseworld.net · 21d ago

Aligos Therapeutics (NASDAQ:ALGS) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Analysis

defenseworld.net · 38d ago

Aligos Therapeutics, Inc. $ALGS Shares Bought by Bank of America Corp DE

globenewswire.com · 40d ago

Aligos Therapeutics to Present at the Cantor Global Healthcare Conference

globenewswire.com · 61d ago

Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China

globenewswire.com · 74d ago

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

globenewswire.com · 91d ago

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

Market news & ticker search · RSS for ALGS

FAQ

What is LOPJLB’s current signal on ALGS?: LOPJLB’s latest quantitative signal on Aligos Therapeutics, Inc. (ALGS) is SELL in a RECOVERY regime. Signals are updated daily.
What market regime is ALGS in?: Aligos Therapeutics, Inc. (ALGS) is currently classified in the RECOVERY HMM market regime on LOPJLB.
What does Aligos Therapeutics, Inc. (ALGS) do?: Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset…

Aligos Therapeutics, Inc. (ALGS)

Key stats

Prediction markets

Company news

FAQ